Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

Objective. To evaluate effects of tofacitinib or adalimumab on patient-reported outcomes (PROs) in patients with moderate to severe RA and inadequate responses to MTX. Methods. In this 12-month, phase 3, randomized controlled trial (ORAL Standard), patients (n = 717) receiving background MTX were ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, van Vollenhoven, Ronald F., Lee, Eun Bong, Fleischmann, Roy, Zwillich, Samuel H., Gruben, David, Koncz, Tamas, Wilkinson, Bethanie, Wallenstein, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870388/
https://www.ncbi.nlm.nih.gov/pubmed/26929445
http://dx.doi.org/10.1093/rheumatology/kev442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870388/
https://www.ncbi.nlm.nih.gov/pubmed/26929445
http://dx.doi.org/10.1093/rheumatology/kev442

Ejemplares similares